Drugs / OK-432
OK-432
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05085990 | May 2023 → Sep 2024 | urinary bladder carcinoma | Protara Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05085977 | Mar 2022 → Sep 2024 | urinary bladder carcinoma | Protara Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01149902 | Jul 2010 → Mar 2012 | head and neck cancer | University of Yamanashi | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00795977 | Nov 2003 → Nov 2011 | malignant pancreatic neoplasm | Fukushima Medical University | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05871970 | Oct 2023 → Dec 2026 expected | lymphatic malformation | Protara Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05951179 | Sep 2023 → Oct 2031 expected | non-invasive bladder urothelial carcinoma | Protara Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT03427619 | Oct 2005 → Apr 2018 | lymphatic malformation | Richard JH Smith | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00010452 | Apr 2000 → Jun 2006 | lymphatic malformation | University of Iowa | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07480356 | May 2026 → Apr 2028 expected | bladder carcinoma in situ | Protara Therapeutics | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01699347 | Sep 2012 → Jan 2014 | — | Carmel Medical Center | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02502643 | Jul 2015 → Jul 2018 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OK-432 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02502643 ↗ |
| Known as | OK432 (Picibanil) | “OK432 (Picibanil)” NCT01699347 ↗ |
| Known as | picibanil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00010452 ↗ |
| Known as | TARA-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05951179 ↗ |
| Modality | Other / unclassified | “the immunostimulant OK-432 (Picibanil)” PMID 19117316 ↗ Jan 2009 |
| Route | Other | “Patients receive an intralesional injection of picibanil (OK432) with the aid of ultrasonography or transillumination for localization of cysts.” NCT00010452 ↗ |